In a nutshell This article looked at the outcomes of patients with extensive-stage (ES) small cell lung cancer (SCLC) treated with atezolizumab (Tecentriq), carboplatin (CP; Paraplatin), and etoposide (ET; Etopophos). The authors found that the addition of atezolizumab to CP/ET chemotherapy improved the outcomes of these...
Read MoreEvaluating the impact of stopping early venetoclax treatment in patients with relapsed/refractory chronic lymphocytic leukemia
In a nutshell This study aimed to investigate the impact of venetoclax (Venclexta) modification or early treatment ending on the outcomes of patients with relapsed/refractory chronic lymphocytic leukemia (CLL). This study concluded that venetoclax treatment modification did not impact outcomes but the early ending of...
Read MoreNivolumab improves survival in patients with non-small cell lung cancer in the long-term.
In a nutshell This study looked at 5-year outcomes of patients with previously treated advanced non-small-cell lung cancer (NSCLC) taking nivolumab (Opdivo) compared to docetaxel (Taxotere). The authors found that nivolumab continued to improve the outcomes of these patients after 5 years. Some background NSCLC is the most common...
Read MoreCan exercise improve chemotherapy symptoms in patients with lung cancer?
In a nutshell This article looked at the effectiveness of exercise in improving physical and mental outcomes in patients with lung cancer undergoing chemotherapy (CT). The authors found that supervised exercise improved strength, lung function, and quality of life (QoL) in these patients. Some background Lung cancer is one of the most common...
Read MoreIs nab-paclitaxel a better option than standard solvent-based taxanes for women with breast cancer?
In a nutshell This study explored whether nanoparticle albumin-bound (nab) paclitaxel (Abraxane) is more efficient as chemotherapy before surgery compared to solvent-based (sb) taxanes in patients with breast cancer. The authors found that nab-paclitaxel was able to improve the outcomes of these patients. Some background Breast cancer...
Read MoreComparing two doses of radiotherapy for slow-growing non-Hodgkin lymphomas.
In a nutshell The authors compared a high-dose radiation (24 Gy) in 12 parts with a low-dose radiation (4 Gy) in 2 parts in patients with slow-growing non-Hodgkin lymphomas (NHLs). The study found that the best radiotherapy dose for slow-growing NHLs is 24 Gy in 12 parts after a 5-year follow-up. Some background The current standard of care for...
Read MoreIs omarigliptin safe and effective in insulin-treated patients with uncontrolled type 2 diabetes?
In a nutshell This study looked at the use of omarigliptin (Marizev) in insulin-treated patients with uncontrolled type 2 diabetes (T2D). It found that omarigliptin was well-tolerated and improved blood glucose control. Some background Type 2 diabetes (T2D) is usually treated initially with diet, exercise, and...
Read MoreCan a healthy diet improve quality of life of women with breast cancer undergoing chemotherapy?
In a nutshell This study examined whether a healthy diet can improve the quality of life of women with breast cancer undergoing chemotherapy. The authors found that women who followed healthy dietary advice had an improvement in the quality of their life during chemotherapy, reducing nausea, vomiting, and increasing appetite. Some background...
Read MoreComparing rituximab to newer anti-CD20 monoclonal antibodies for induction therapy of CD20+ B-cell non-Hodgkin lymphomas
In a nutshell This study aimed to compare standard therapy Rituximab (Rituxan) to newer anti-CD20 monoclonal antibodies (mAbs) such as obinutuzumab (Gazyva), ofatumumab (Arzerra), 131I-tositumomab (Bexxar), and 90Y-ibritumomab tiuxetan (Zevalin) for the treatment of patients with B-cell non-Hodgkin lymphomas (B-NHL). The authors concluded...
Read MoreEvaluating carflizomib, lenalidomide, dexamethasone, and cyclophosphamide for newly diagnosed transplant-eligible patients with multiple myeloma.
In a nutshell This study compared a combination therapy of carfilzomib (Kyprolis), lenalidomide (Revlimid), dexamethasone (Decadron), and cyclophosphamide (Cytoxan) to control combination therapies as an alternative treatment regimen in newly diagnosed patients with multiple myeloma (MM). The authors concluded that this regimen provided very good...
Read MoreSexual Health, Communication and Cancer
“I think sexual health is at the intersection of mind/body & relationship factors. When sexual health is disrupted, it’s really important to figure out all the pieces…often folks only hear bits and pieces like “use lube” or “use it or lose it” & “we need a holistic approach!”[1] Dr. Sharon L. Bober,...
Read MoreComparing thulium laser enucleation to bipolar resection to treat benign prostatic hyperplasia
In a nutshell This study looked at functional outcomes of transurethral thulium laser enucleation (THU) versus bipolar transurethral resection of the prostate (TURP) for benign prostate hyperplasia (BPH) over 12-months. The authors found that THU may have better effects than TURP. Some background BPH is the non-cancerous increase in the size...
Read More